Black Diamond Therapeutics reported financial results for the second quarter ended June 30, 2026. The company held $110.5 million in cash and investments as of June 30, sufficient to fund operations into late 2028. Net loss was $9.9 million, with R&D expenses at $7.4 million and G&A expenses at $4.7 million. Clinically, the company presented positive Phase 2 data for silevertinib in frontline non-classical EGFR-mutant NSCLC patients at ASCO, showing a CNS objective response rate of 86% and preliminary median progression-free survival of 15.2 months. The firm plans to provide an update on pivotal development path discussions with the FDA in Q4 2026. Black Diamond Therapeutics is a clinical-stage oncology company developing targeted cancer therapies.